期刊
MOLECULAR DIAGNOSIS & THERAPY
卷 16, 期 1, 页码 15-27出版社
ADIS INT LTD
DOI: 10.1007/BF03256426
关键词
-
资金
- Vita Genomics, Inc.
- National Science Council, Taiwan [NSC-97-2314-B-039-006-MY3, NSC-100-2627-B-039-001]
- National Health Research Institutes, Taiwan [NHRI-EX-101-9904NI]
- Taiwan Department of Health Clinical Trial and Research Center of Excellence [DOH101-TD-B-111-004]
- China Medical University Hospital, Taiwan [DMR-98-092, DMR-99-115]
In pharmacogenomics studies, gene-gene interactions play an important role in characterizing a trait that involves complex pharmacokinetic and pharmacodynamic mechanisms, particularly when each involved feature only demonstrates a minor effect. In addition to the candidate gene approach, genome-wide association studies (GWAS) are widely utilized to identify common variants that are associated with treatment response. In the wake of recent advances in scientific research, a paradigm shift from GWAS to wholegenome sequencing is expected, because of the reduced cost and the increased throughput of next-generation sequencing technologies. This review first outlines several promising methods for addressing gene-gene interactions in pharmacogenomics studies. We then summarize some candidate gene studies for various treatments with consideration of gene-gene interactions. Furthermore, we give a brief overview for the pharmacogenomics studies with the GWAS approach and describe the limitations of these GWAS in terms of gene-gene interactions. Future research in translational medicine promises to lead to mechanistic findings related to drug responsiveness in light of complex gene-gene interactions and will probably make major contributions to individualized medicine and therapeutic decision-making.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据